ethyl 3-<2-hydroxy-4-(methoxymethoxy)phenyl>propanoate | 80754-22-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: ethyl 3-<2-hydroxy-4-(methoxymethoxy)phenyl>propanoate
• 英文别名: ethyl 3-(2-hydroxy-4-methoxymethoxyphenyl)propionate；3-[2-hydroxy-4-(methoxymethoxy)phenyl]propanoic acid ethyl ester；ethyl 3-[2-hydroxy-4-(methoxymethoxy)phenyl]propanoate
• CAS: 80754-22-9
• 化学式: C₁₃H₁₈O₅
• 分子量: 254.283
• InChiKey: KWJKKVIOXDVLFW-UHFFFAOYSA-N

物化性质

• 沸点：
  384.1±37.0 °C(Predicted)
• 密度：
  1.152±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  18
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  65
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  ethyl 3-<2-hydroxy-4-(methoxymethoxy)phenyl>propanoate 在 lithium aluminium tetrahydride 、 仲丁基锂 、 potassium carbonate 、 二甲基亚砜 、 pyridinium chlorochromate 作用下， 以 乙醚 、 二氯甲烷 、 丙酮 为溶剂， 反应 13.33h， 生成 xenognosin A
  参考文献：
  名称：

  Synthesis and carbon-13 nuclear magnetic resonance assignments of xenognosin

  摘要：

  DOI：

  10.1021/jo00347a032
• 作为产物：
  描述：

  7-羟基香豆素 在 palladium on activated charcoal sodium hydroxide 、 methyltrialkyl(C₈-C₁₀)ammonium chloride (Adogen 464) 、 氢气 作用下， 以 二氯甲烷 为溶剂， 反应 26.0h， 生成 ethyl 3-<2-hydroxy-4-(methoxymethoxy)phenyl>propanoate
  参考文献：
  名称：

  Synthesis and carbon-13 nuclear magnetic resonance assignments of xenognosin

  摘要：

  DOI：

  10.1021/jo00347a032

文献信息

• Alkanoic acid derivatives process for their production and use thereof
  申请人：——

  公开号：US20040058965A1

  公开（公告）日：2004-03-25

  An alkanoic acid derivative useful as a prophylactic or therapeutic agent of diabetes mellitus, hyperlipidemia, impaired glucose tolerance and the like can be provided by a compound represented by the formula 1 wherein R 1 is an optionally substituted 5-membered aromatic heterocyclic group; X is a bond and the like; Q is a divalent hydrocarbon group having 1 to 20 carbon atoms; Y is a bond and the like, ring A is an aromatic ring optionally further having 1 to 3 substituents; Z is —(CH 2 ) n —Z 1 — (n is an integer of 1 to 8 and Z 1 is an oxygen atom and the like) and the like; ring B is a pyridine ring optionally further having 1 to 3 substituents, and the like; U is a bond and the like; W is a divalent hydrocarbon group having 1 to 20 carbon atoms; and R 3 is —OH and the like, provided that, when ring B is a benzene ring optionally further having 1 to 3 substituents, U should be a bond, or a salt thereof.

  一种可以用作糖尿病、高脂血症、糖耐量受损等预防或治疗剂的脂肪酸衍生物可以由以下式1所表示的化合物提供，其中R1是可选取代的5-成员芳香杂环基；X是键等；Q是具有1到20个碳原子的二价碳氢基团；Y是键等；环A是一种芳香环，可选择进一步具有1到3个取代基；Z是—（CH2）n—Z1—（n是1到8的整数，Z1是氧原子等）等；环B是吡啶环，可选择进一步具有1到3个取代基等；U是键等；W是具有1到20个碳原子的二价碳氢基团；R3是—OH等；但是，当环B是苯环，可选择进一步具有1到3个取代基时，U应为键，或其盐。
• Arylalkanoic Acid Derivative
  申请人：Maekawa Tsuyoshi

  公开号：US20080051418A1

  公开（公告）日：2008-02-28

  A compound represented by the formula (I): wherein Ar is an optionally substituted aromatic ring; Xa, Xc, Ya, Yc, Z 1 and Z 2 are each a bond, O, S, —CO—, —CS—, —CR 3 (OR 4 )—, —NR 5 —, —SO—, —SO 2 —, —CONR 6 — or —NR 6 CO— (wherein R 3 , R 4 , R 5 and R 6 are as defined in the specification); Xb and Yb are each a bond or a divalent hydrocarbon group having 1 to 20 carbon atoms; R 1 is an optionally substituted hydrocarbon group; ring A is an optionally further substituted aromatic ring, provided that the ring should not be benzimidazole; n is an integer of 1 to 8; ring B is an optionally further substituted aromatic ring, provided that the ring should not be oxazole; W is a divalent saturated hydrocarbon group having 1 to 20 carbon atoms; and R 2 is —OR 8 or —NR 9 R 10 (wherein R 8 , R 9 and R 10 are as defined in the specification) or a salt thereof, is useful as an agent for the prophylaxis or treatment of diabetes and the like.

  化合物式(I)所代表的复合物，其中Ar是一个可选择性取代的芳香环；Xa、Xc、Ya、Yc、Z1和Z2分别是键合、O、S、—CO—、—CS—、—CR3(OR4)—、—NR5—、—SO—、—SO2—、—CONR6—或—NR6CO—（其中R3、R4、R5和R6如规范中所定义）；Xb和Yb分别是一个键合或具有1到20个碳原子的二价碳氢基团；R1是一个可选择性取代的碳氢基团；环A是一个可选择性进一步取代的芳香环，但不应为苯并咪唑；n是1到8的整数；环B是一个可选择性进一步取代的芳香环，但不应为噁唑；W是一个具有1到20个碳原子的二价饱和碳氢基团；和R2是—OR8或—NR9R10（其中R8、R9和R10如规范中所定义）或其盐，用作预防或治疗糖尿病等疾病的药剂。
• Therapeutic agent for diabetes
  申请人：Abe Hidenori

  公开号：US20090270631A1

  公开（公告）日：2009-10-29

  The present invention provides an agent for the prophylaxis or treatment of diabetes, which is associated with a fewer side effects such as body weight gain, adipocyte accumulation, cardiac hypertrophy and the like, and which contains a compound represented by the formula: wherein each symbol is as defined in the specification, or a salt thereof or a prodrug thereof.

  本发明提供了一种用于预防或治疗糖尿病的药剂，其具有较少的副作用，例如体重增加、脂肪细胞积聚、心脏肥大等，并且包含以下式子所表示的化合物：其中每个符号如规范中所定义，或其盐或前药。
• Therapeutic Agent for Diabetes
  申请人：Abe Hidenori

  公开号：US20080009530A1

  公开（公告）日：2008-01-10

  The present invention provides an agent for the prophylaxis or treatment of diabetes, which is associated with a ferwer side effects such as body weight gain, adipocyte accumulation, cardiac hypertrophy and the like, and which contains a compound represented by the formula: wherein each symbol is as defined in the specification, or a salt thereof or a prodrug thereof.

  本发明提供一种用于预防或治疗糖尿病的药剂，其与体重增加、脂肪细胞积累、心肌肥大等副作用相关，其中包含一种由以下式表示的化合物：其中每个符号如规范中所定义，或其盐或前药。
• ARYLALKANOIC ACID DERIVATIVE
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1829863A1

  公开（公告）日：2007-09-05

  A compound represented by the formula (I): wherein Ar is an optionally substituted aromatic ring; Xa, Xc, Ya, Yc, Z1 and Z2 are each a bond, O, S, -CO-, -CS-, - CR3 (OR4) -, -NR5-, -SO-, -SO2-, -CONR6- or -NR6CO- (wherein R3, R4, R5 and R6 are as defined in the specification); Xb and Yb are each a bond or a divalent hydrocarbon group having 1 to 20 carbon atoms; R1 is an optionally substituted hydrocarbon group; ring A is an optionally further substituted aromatic ring, provided that the ring should not be benzimidazole; n is an integer of 1 to 8; ring B is an optionally further substituted aromatic ring, provided that the ring should not be oxazole; W is a divalent saturated hydrocarbon group having 1 to 20 carbon atoms; and R2 is -OR8 or -NR9R10 (wherein R8, R9 and R10 are as defined in the specification) or a salt thereof, is useful as an agent for the prophylaxis or treatment of diabetes and the like.

  式 (I) 所代表的化合物： 其中 Ar 是任选取代的芳香环； Xa、Xc、Ya、Yc、Z1 和 Z2 各自是键、O、S、-CO-、-CS-、-CR3 (OR4)-、-NR5-、-SO-、-SO2-、-CONR6- 或-NR6CO-（其中 R3、R4、R5 和 R6 如说明书中所定义）； Xb 和 Yb 分别为键或具有 1 至 20 个碳原子的二价烃基； R1 是任选取代的烃基； 环 A 是任选进一步取代的芳香环，但该环不能是苯并咪唑； n 是 1 至 8 的整数； 环 B 是任选被进一步取代的芳香环，条件是该环不能是噁唑； W 是具有 1 至 20 个碳原子的二价饱和烃基；以及 R2 是-OR8 或-NR9R10（其中 R8、R9 和 R10 如说明书中所定义） 或其盐、 可用作预防或治疗糖尿病等疾病的药物。